GBG Forschungs GmbH (German Breast Group)

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. (2020) Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, et al. Journal article, Review article Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study) (2020) Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, et al. Journal article MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial (2020) Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, Marmé F, et al. Journal article Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo (2020) Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, Higgs BW, et al. Journal article Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy (2020) Daillere R, Derosa L, Bonvalet M, Segata N, Routy B, Gariboldi M, Budinska E, et al. Journal article, Review article Association of Germline Variant Status with Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial (2020) Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching P, Kayali M, et al. Journal article Human leucocyte antigen class i in hormone receptor-positive, HER2-negative breast cancer: Association with response and survival after neoadjuvant chemotherapy (2019) Sinn BV, Weber KE, Schmitt WD, Fasching P, Symmans WF, Blohmer JU, Karn T, et al. Journal article Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019) Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al. Conference contribution Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019) Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al. Conference contribution Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution